Evidence map›Paper›PMID 24302499›Full record

ArticleProteomics. Clinical applications2014

Comparison of two phenotypically distinct lattice corneal dystrophies caused by mutations in the transforming growth factor beta induced (TGFBI) gene.

Ebbe Toftgaard Poulsen, Kasper Runager, Michael W Risør, Thomas F Dyrlund, Carsten Scavenius, Henrik Karring, Jeppe Praetorius, Henrik Vorum, Daniel E Otzen, Gordon K Klintworth and 1 more

Abstract read
In one paragraph

Article in Proteomics. Clinical applications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Classic lattice corneal dystrophy: a brief review and summary of treatment modalities.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Proteomics and the eye.Proteomics. Clinical applications · 2014
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Ebbe Toftgaard PoulsenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark; Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Aarhus, Denmark; Center for Insoluble Protein Structures (inSPIN), Aarhus University, Aarhus, Denmark.
Kasper Runager
Michael W Risør
Thomas F Dyrlund
Carsten Scavenius
Henrik Karring
Jeppe Praetorius
Henrik Vorum
Daniel E Otzen
Gordon K Klintworth
Jan J Enghild
Aarhus University · DKAalborg University Hospital · DKDuke University Hospital · USUniversity of Southern Denmark · DK

Funding

BIGH3 WILD TYPE AND MUTANT PROTEINSR01EY012712 · NEI · DUKE UNIVERSITY · PI KLINTWORTH, GORDON KENNETH · 1999 to 2011
$2.4M
NEI NIH HHS R01 EY012712
6 · The paper itself

Abstract

purposeIn this study, we investigated whether the phenotypic difference observed between two lattice corneal dystrophy type 1 (LCD type 1) cases caused by either a single A546D substitution or an A546D/P551Q double substitution in TGFBIp (transforming growth factor beta induced protein) can be ascribed to (i) a difference in the proteomes of corneal amyloid deposits, (ii) altered proteolysis of TGFBIp, or (iii) structural changes of TGFBIp introduced by the P551Q amino acid substitution. EXPERIMENTAL

designAmyloid deposits were isolated from the corneas of two siblings with LCD type 1 resulting from A546D/P551Q mutations in the TGFBI gene using laser capture microdissection and subsequently analyzed by LC-MS/MS. Proteolytic processing of TGFBIp was addressed by counting peptide spectra. Lastly, to study the possible effect of the P551Q substitution, recombinant FAS1-4 domain variants were subjected to in vitro stability assays.

resultsThe amyloid proteomes and TGFBIp processing of the two A546D/P551Q LCD type 1 cases were similar to each other as well as to the A546D amyloid proteome previously reported by us. The stability assays revealed a minor destabilization of the FAS1-4 domain upon the addition of the P551Q mutation, moreover, it resulted in different accessibility to tryptic cleavage sites between the A546D and A546D/P551Q mutant FAS1-4 domain variants. CONCLUSION AND CLINICAL RELEVANCE: The difference in A546D and A546D/P551Q LCD type 1 phenotypes cannot be ascribed to altered corneal amyloid composition or altered in vivo proteolytic processing of TGFBIp. Instead, a small difference in thermodynamic stability introduced by the P551Q mutation most likely causes structural changes of TGFBIp. The MS proteomics data have been deposited to the ProteomeXchange with identifier PXD000307 (http://proteomecentral.proteomexchange.org/dataset/PXD000307).

Indexed as

Amino Acid SubstitutionAmyloidbetaIG-H3 ProteinChromatography, LiquidCorneaCorneal Dystrophies, HereditaryExtracellular Matrix ProteinsHumansLaser Capture MicrodissectionMutationProteolysisTandem Mass SpectrometryTransforming Growth Factor betaAmyloidbetaIG-H3 ProteinExtracellular Matrix ProteinsTransforming Growth Factor betaAmyloid depositsCorneaLaser capture microdissectionLattice corneal dystrophyParaffin-embedded tissue

Identifiers

PMID24302499
PMCPMC4163973
OpenAlexW2134042712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.